Osimertinib and FLAURA: the assay defines the first-line opportunity

Clarus Biotech Review

An EGFR-selected trial demonstrates why population definition belongs in the clinical and access model.

FLAURA makes biomarker selection concrete. The phase III trial randomized 556 previously untreated patients with advanced non-small-cell lung cancer carrying an EGFR exon 19 deletion or L858R mutation. Osimertinib was compared with gefitinib or erlotinib, rather than with an unselected lung-cancer population. [1]

## The measured benefit has a boundary

The primary analysis reported median progression-free survival of 18.9 months versus 10.2 months, with a hazard ratio of 0.46. These results concern the trial-defined population and comparator. They do not imply that any EGFR-related laboratory signal identifies the same treatment opportunity. Nor should progression-free survival be relabeled as overall survival. [1]

## Regulatory wording makes testing operational

The April 2018 FDA label specified first-line metastatic NSCLC with the relevant mutations detected by an FDA-approved test. The diagnostic condition therefore sits inside the product's use definition. The test is not an optional commercial segmentation tool; it is a dependency connecting biology, eligibility, and treatment. [2]

## From total disease burden to reachable patients

A commercial model should distinguish disease incidence, mutation prevalence, completed testing, actionable results, clinical suitability, coverage, and initiation. Multiplying a broad cancer population by a generic conversion rate hides where access can break. For a biomarker-led program, time to an interpretable result can matter as much as nominal testing availability.

## Build the study and launch measurement system together

Before a pivotal readout, connect the specimen pathway, assay reproducibility, result-reporting process, and treatment-selection rules. For the operating dashboard, track the fraction of eligible workups with usable results and the time from sample collection to a decision. FLAURA supports a particular drug-population proposition; the broader lesson is to make the diagnostic dependency measurable before expanding the opportunity narrative.

Source adaptation: the BioClarus biomarker-planning paper informs the assay-and-population questions. The case evidence here comes from FLAURA and the historical FDA label.

Sources

https://pubmed.ncbi.nlm.nih.gov/29151359/

https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208065s008lbl.pdf

Original article: https://www.clarusreview.bio/articles/biomarker-enrichment-evidence-plan